EEG signature analysis for drug repurposing for rare diseases
Active Project Grant Awarded Last action
- Award ID
- R44MH138151
- Recipient
-
Psychogenics Inc. UEI YXMNA8N7LFG4
- Awarding agency
-
National Institute of Mental Health
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,944,876
Award facts
- Assistance listing
- 93.242 Mental Health Research Grants
- Completion date 56% complete
- Originally
- Place of performance
- Paramus, NJ 07652, USA
Award details come from USAspending.gov.
Description
- Abstract
- The high rate of failure in CNS drug discovery, in particular of the first-in-class therapeutics with new modes of action, highlights a clear unmet need to improve the success rate in drug discovery for rare diseases and psychiatric disorders. One well-known issue is the high cost, high risk, and low development time for drug development, time, and costs that most of the 10,000 rare disorder patients and support organizations cannot afford to support or wait for. Another important issue is the lack of clear targets for many for most rare diseases, which are complex and may require polypharmacology. Phenotypic screening platforms are well-suited for drug repurposing of drug in a target-agnostic manner. Suitable proven in vivo phenotypic screens, however, are scarce with the exception of psychogenics smartcube® platform, which has been developed in the past few years for drug repurposing approaches using behavioral data, combining reference drugs' signatures, and comparing them against disease animal models' signatures. Our aim for this fast track project is to create a similar repurposing platform based on EEG data, using our ecube® fast EEG platform. To do this we will assess in ecube® several animal models of rare disease to create a small database, increase our reference drug EEG database, and use a novel algorithm, called drug EEG signature analysis (desa) to compare the two datasets and generate at once a multitude of hypotheses for potential drug repurposing. These hypotheses to be evaluated empirically using such models of disease. If our phase i proof of concept project is successful, we will use the phase II period to get the platform ready for commercialization. If successful, this platform will be an innovative and unique drug repurposing platform, offered as fee-for-service or used in drug development by PGI and its partners.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $924,001 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $460,234 | |
| Original award | $560,641 |
Quick answers
Who received award R44MH138151?
R44MH138151 was awarded to Psychogenics Inc. by National Institute of Mental Health (National Institutes of Health) on August 5, 2024.
How much is award R44MH138151 worth?
$1,944,876 has been obligated on R44MH138151.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award